$410m Ambit deal bolsters Daiichi Sankyo's oncology presence
This article was originally published in Scrip
Daiichi Sankyo is to purchase US oncology-focused venture Ambit Biosciences for up to $410m, bringing the major Japanese firm an attractive Phase III asset for acute myeloid leukemia and boosting its oncology pipeline.
You may also be interested in...
Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.
In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.
In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.